期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 25, 期 2, 页码 133-141出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2012.04.007
关键词
non-Hodgkin's lymphoma; proteasome inhibitor; mantle cell lymphoma; bortezomib; carfilzomib
类别
资金
- NIH [1P50CA130805, 1P50CA142509-01, RC2CA148431-01, CA 100866, CA93738]
- Multiple Myeloma Foundation
- Leukemia and Lymphoma Society of America
- Multiple Myeloma Research Foundation
Mantle cell lymphoma (MCL) represents a subtype of non-Hodgkin's lymphoma (NHL) which has a relatively poor prognosis compared to other forms of NHL Despite multiple options for cytotoxic chemotherapy, attempts to prolong the survival of patients with this disease have not yet met with success. Consequently, the development of targeted approaches to therapy which minimize toxicities has potentially important implications for MCL. Proteasome inhibitors preferentially kill transformed cells through diverse mechanisms. The proteasome inhibitor bortezomib was initially approved for patients with relapsed or refractory multiple myeloma and now has been approved for relapsed or refractory mcL. The introduction of newer proteasome inhibitors with activity in bortezomib-resistant disease and reduced toxicity profiles may yield further benefits. Multiple ongoing studies are building on the known efficacy of proteasome inhibitors in MCL by evaluating combination regimens involving either cytotoxic or targeted therapies, with the ultimate goal of prolonging survival in this patient population. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据